PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32949655-7	2020	Fenofibrate increased A-FABP but did not change LCN2 levels.	Fenofibrate	0-11	fatty acid binding protein 4	Homo sapiens	22-28	
32949655-9	2020	Fenofibrate increased A-FABP modestly but did not affect LCN2 levels.	Fenofibrate	0-11	fatty acid binding protein 4	Homo sapiens	22-28	
23144467-2	2012	OBJECTIVE: This study aimed to investigate the long-term effect of fenofibrate therapy on three novel biomarkers of cardiovascular risk, namely adipocyte-fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF21), and retinol-binding protein 4 (RBP4), which are all downstream targets of PPAR-alpha or PPAR-gamma, in patients with type 2 diabetes.	Fenofibrate	67-78	fatty acid binding protein 4	Homo sapiens	144-180	
23144467-2	2012	OBJECTIVE: This study aimed to investigate the long-term effect of fenofibrate therapy on three novel biomarkers of cardiovascular risk, namely adipocyte-fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF21), and retinol-binding protein 4 (RBP4), which are all downstream targets of PPAR-alpha or PPAR-gamma, in patients with type 2 diabetes.	Fenofibrate	67-78	fatty acid binding protein 4	Homo sapiens	182-188	
23144467-5	2012	RESULTS: Relative to the placebo group, the changes of serum FGF21 and RBP4 levels were 85% (P < 0.001) and 10% (P = 0.032) higher in the fenofibrate group, respectively, over 5 yr. Fenofibrate treatment had no detectable effect on serum A-FABP level (P > 0.05).	Fenofibrate	141-152	fatty acid binding protein 4	Homo sapiens	241-247